Immunome, Inc. (NASDAQ:IMNM) Receives $29.80 Consensus Target Price from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have received an average rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $29.80.

A number of brokerages have weighed in on IMNM. JPMorgan Chase & Co. assumed coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 price target for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Tuesday, May 14th. Guggenheim initiated coverage on Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Piper Sandler started coverage on Immunome in a research note on Friday, May 31st. They set an “overweight” rating and a $27.00 price target for the company.

Immunome Trading Up 0.8 %

NASDAQ IMNM opened at $12.20 on Friday. The company’s fifty day simple moving average is $14.29 and its 200-day simple moving average is $17.17. Immunome has a 52 week low of $6.13 and a 52 week high of $30.96. The stock has a market cap of $731.63 million, a P/E ratio of -1.62 and a beta of 1.79.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.46. The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $4.00 million. Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. On average, research analysts expect that Immunome will post -1.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jean Jacques Bienaime purchased 2,000 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was bought at an average price of $13.57 per share, with a total value of $27,140.00. Following the completion of the purchase, the director now owns 9,615 shares in the company, valued at approximately $130,475.55. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Redmile Group LLC increased its position in Immunome by 26.0% in the first quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock worth $120,674,000 after buying an additional 1,010,139 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Immunome by 113.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after buying an additional 1,194,451 shares during the last quarter. Vanguard Group Inc. raised its position in Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after purchasing an additional 279,712 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Immunome by 10.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock worth $37,957,000 after purchasing an additional 146,943 shares in the last quarter. Finally, Avidity Partners Management LP bought a new position in Immunome during the fourth quarter valued at approximately $14,268,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.